Using statistics can can improve clinical trials and outcomes – Dimitris Bertsimas

MIT Sloan Professor Dimitris Bertsimas

MIT Sloan Professor Dimitris Bertsimas

From Times Higher Education 

Sometimes science can be personal. When my father, who was living in Greece at the time, was diagnosed with stage IV gastric cancer in 2007, I set out to find the best possible care for him. As is the case with many patients with advanced disease, drug therapy was his best course. So, after unsuccessful surgery in Greece, he came to the US for treatment.

I contacted the most prestigious cancer hospitals in the country and found that they all used different drugs in different treatment regimens to treat advanced gastric cancer. As both a son and a scientist, I was surprised to discover that there was no standard treatment – something I would later realise was true of many different kinds of late-stage cancers.

Read More »

A bold new way to fund drug research — Roger Stein

MIT Sloan Senior Lecturer Roger Stein

MIT Sloan Senior Lecturer Roger Stein

From TED

Believe it or not, about 20 years’ worth of potentially life-saving drugs are sitting in labs right now, untested. Why? Because they can’t get the funding to go to trials; the financial risk is too high. Roger Stein is a finance guy, and he thinks deeply about mitigating risk. He and some colleagues at MIT came up with a promising new financial model that could move hundreds of drugs into the testing pipeline. (Filmed at TED@StateStreet.)

Roger Stein wants to bring financial engineering to the world of drug funding.

Watch the video on the TED site.

Roger Stein is a Senior Lecturer of Finance at the MIT Sloan School of Management.